ADVICENNE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.746 EUR | +2.83% |
|
+7.51% | -34.36% |
| Apr. 08 | Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 25 | Advicenne: ODD designation in cystinuria | CF |
Business Summary
At the end of 2023, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.
Number of employees: 21
Sales per Business
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -12.32% |
Sales per region
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
European Union
95.7
%
| 3 | 97.5 % | 2 | 95.7 % | -13.91% |
Rest of the World
4.3
%
| 0 | 2.5 % | 0 | 4.3 % | +49.25% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Didier Laurens
CEO | Chief Executive Officer | 59 | 21-05-02 |
| Chief Tech/Sci/R&D Officer | - | 23-03-31 | |
André Ulmann
BRD | Director/Board Member | - | 17-06-22 |
| Corporate Officer/Principal | - | 21-06-30 | |
Nathalie Lemarié
LAW | General Counsel | - | 12-09-27 |
| Corporate Officer/Principal | - | 07-12-31 | |
Hege Hellstrom
PRN | Corporate Officer/Principal | 59 | 20-05-25 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 11-04-28 | |
Catherine Dunand
BRD | Director/Board Member | 62 | 17-03-08 |
Didier Laurens
CEO | Chief Executive Officer | 59 | 21-05-02 |
Thibaut Roulon
BRD | Director/Board Member | - | 11-04-28 |
André Ulmann
BRD | Director/Board Member | - | 17-06-22 |
Charlotte Sibley
BRD | Director/Board Member | 77 | 18-09-19 |
Hege Hellstrom
PRN | Corporate Officer/Principal | 59 | 20-05-25 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 12,446,961 | 10,980,696 ( 88.22 %) | 28,884 ( 0.2321 %) | 88.22 % |
Company contact information
Sector
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.746
EUR
Average target price
6.9
EUR
Spread / Average Target
+295.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.36% | 22.19M | |
| -6.35% | 84.57B | |
| +3.95% | 39.93B | |
| -26.37% | 27.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B |
- Stock Market
- Equities
- ALDVI Stock
- Company Advicenne
